POWERFUL NEWS:

MMRF PRESS RELEASES


Multiple Myeloma Research Foundation Awarded 4-Star Rating from Charity Navigator


New Canaan, Conn. — January 9, 2006
Cancer Foundation Recognized Third Year Running for Outstanding Fiscal Management

The Multiple Myeloma Research Foundation (MMRF) announced today that for a third consecutive year, the MMRF has received a 4-star rating from Charity Navigator, America's largest independent evaluator of charitable organizations. Fewer than 12 percent of the 1.5 million charities evaluated annually receive this distinction for two consecutive years.

The 4-star rating, the highest honor Charity Navigator bestows, goes to organizations operating with exceptional standards of fiscal responsibility. Spending only $3 to raise $100, the MMRF exceeds standards in cancer fundraising and outperforms most charities in America for responsible management and measurable results. More than 95 percent of the dollars raised goes toward research and related programming.

"To be evaluated by a credible third-party and found worthy of the public's trust is essential to our success," said Scott Santarella, Executive Director and Chief Administrative Officer of the MMRF. "As an organization we feel an immense obligation to our donors to be responsible stewards of their support. This rating validates our efforts and we are proud to once again be recognized by Charity Navigator for our commitment toward fiscal responsibility."

In addition to the 4-star rating from Charity Navigator, the MMRF was the only cancer-related charity to recently receive the "A+" designation from the American Institute of Philanthropy, and is in compliance with all of the Better Business Bureau's Wise Giving Alliance standards for charity accountability. Additionally, the MMRF has earned approval from the National Cancer Institute (NCI) for its research grants program, making it one of only nine private, charitable research organizations that meet the same rigorous scientific standards the NCI applies to its own grant issuing process.

About Multiple Myeloma

The second most common hematologic (blood) cancer, multiple myeloma, which affects the plasma cell, represents one percent of all cancer diagnosis and two percent of all cancer deaths. Despite recent advances in treating myeloma, the five-year survival rate for multiple myeloma is only 32 percent.

Approximately 46,000 people in the United States are living with multiple myeloma and an estimated 14,600 new cases are diagnosed each year. Although the peak age of onset of multiple myeloma is 65 to 70 years of age, recent statistics suggest that incidence is increasing and at an earlier age.

About the Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, a newly diagnosed multiple myeloma patient, with the unique mission of accelerating the search for a cure for multiple myeloma. Today, the MMRF is the largest non–profit foundation dedicated to the single mission of accelerating the search for a cure for multiple myeloma. As the world's number one funder of myeloma research, the MMRF has raised more than $50 million to fund more than 140 research grants at 57 research institutions around the globe. Currently, the MMRF is funding more than 20 new compounds and approaches – in pre–clinical testing and Phase I, II and III clinical trials – that show promise in treating patients at all stages of the disease. For more information about the MMRF, please visit www.themmrf.org.

For more information, please contact:
Scott Santarella
Multiple Myeloma Research Foundation
203-972-1250
santarellas@www.themmrf.org

Krista Richardson
Fleishman-Hillard
212-453-2412
richardk@fleishman.com